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Adapting clinical guidelines to take account of
multimorbidity
Care of patients with multimorbidity could be improved if new technology is used to bring together
guidelines on individual conditions and tailor advice to each patient’s circumstances, say Bruce
Guthrie and colleagues
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Most people with a chronic condition have multimorbidity, but
clinical guidelines almost entirely focus on single conditions.
It will never be possible to have good evidence for every
possible combination of conditions, but guidelines could be
made more useful for people with multimorbidity if they were
delivered in a format that brought together relevant
recommendations for different chronic conditions and identified
synergies, cautions, and outright contradictions. We highlight
the problem that multimorbidity poses to clinicians and patients
using guidelines for single conditions and propose ways of
making them more useful for people with multimorbidity.
Guidelines and multimorbidity
Guidelines have the potential to improve the care of people with
chronic disease1 but seldom explicitly account for people with
multiple conditions. This reflects the way in which clinical
evidence is created but does not match everyday practice, where
multimorbidity is common. The figure⇓ illustrates this using
data fromUK primary care electronic health records taken from
a study of the prevalence of multimorbidity in 1.75 million
people.2 Most people with any chronic condition have multiple
conditions, and although the degree of multimorbidity increases
with age, this applies to younger patients as well, particularly
those living in themost socioeconomically deprived areas, where
multimorbidity develops 10-15 years earlier than in more
affluent areas.2
Clinical decision making is more difficult in people with
multimorbidity because clinicians and patients often struggle
to balance the benefits and risks of multiple recommended
treatments3 and because patient preference rightly influences
the application of clinical and economic evidence.4 Robust
synthesis of clinical and economic evidence produces rational
guidance for individual conditions, but combining
recommendations for patients with multimorbidity can result
in harmful or burdensome overall treatment regimens.5 6 Take,
for an example, an older person with chronic obstructive
pulmonary disease, type 2 diabetes, osteoporosis, hypertension,
and osteoarthritis. When US guidelines for these conditions
were examined, only one of the five explicitly acknowledged
potential comorbidity, and the recommendations made were
sometimes contradictory and implied a drug and self care
regimen that would be unfeasible for many patients.6 Similar
problems apply to National Institute for Health and Clinical
Excellence (NICE) guidelines in the UK.7
Polypharmacy is an important consequence of following
guidelines in people with multimorbidity.6 7 Polypharmacy can
be appropriate, but it is associated with riskier prescribing8 and
is often particularly problematic in people who are physically
frail or have cognitive impairment. Additionally, single disease
guidelines rarely explicitly consider applicability to individuals
with limited life expectancy, who are unlikely to benefit from
long term preventive treatment,4 9 and virtually never make
recommendations about when chronic treatments should be
stopped.
We therefore need to design new forms of clinical guidelines
and evidence summaries that support informed initiation—and
cessation—of treatment for chronic disease in people with
multiple conditions. The main target audience is generalist
clinicians with overall responsibility for a patient rather than a
disease focus, but specialists also need to consider the effect of
their recommendations on their patients since they will usually
be being treated for other conditions.
Correspondence to: B Guthrie b.guthrie@dundee.ac.uk
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;345:e6341 doi: 10.1136/bmj.e6341 (Published 4 October 2012) Page 1 of 5
Analysis
ANALYSIS
How can guidelines better inform
treatment of people with multimorbidity?
Although similar problems arise in terms of the cumulative
burden of non-pharmacological treatments, we focus on
decisions about medicines for chronic conditions, since this is
where the accumulation of individual disease recommendations
is most problematic. We propose several ways to improve
existing guidelines.
Cross reference guidelines using electronic
delivery
Reflecting the way that they are created, existing guidelines
require clinicians and patients to read separate documents for
every condition that a patient has, and there is little cross
referencing between guidelines. A notable exception is the NICE
guideline on depression in adults with a chronic physical health
problem, which provides advice on choice of antidepressant
medicine depending on physical comorbidity and coprescribing,
as well as guidance on collaborative care approaches when there
is evidence that they improve physical or depression outcomes.10
Although cross referencing existing guidelines for all possible
combinations of conditions would rapidly make them
unreadable, this could be overcome by using electronic formats
that present different recommendations depending on
demographic and clinical information provided through
screening questions (if web based) or coded data (if embedded
in electronic health records).
Simple versions that only recommend treatments to consider
starting, avoiding, or stopping would be potentially useful as a
starting point while more complex, fully cross referenced
versions are developed and tested. Such development should
be informed by the patterns of comorbidity that are most
common. For example, dementia is rarely a comorbidity of
common physical conditions (fig 1⇓),2 but many people with
dementia have physical conditions. Cross referencing in this
situation is likely to be predominantly in terms of the
management of physical conditions in people with dementia.
In contrast, depression and pain are common comorbidities of
many other conditions, implying that most clinical guidelines
should explicitly cross reference specific guidance as NICE
already does for depression. Developing systematic and
appropriate cross referencing is no small task, but it is only what
individual clinicians are expected to do every day for individual
patients.
The table⇓ shows an example of simple cross referencing of
recommended chronic drug treatments for a 76 year old woman
with hypertension,11 atrial fibrillation,12 osteoarthritis,13 and
moderately severe depression.10 14 Depending on response to
treatment, between three and eight drugs are recommended with
several important cautions and relative contraindications that
should influence treatment choice. Although not the focus here,
guidelines often also make lifestyle and self care
recommendations that also overlap in complex ways,6 7 notably
in this case those relating to exercise for hypertension,
osteoarthritis, and depression.10-14
People with multimorbidity will also commonly have patterns
of illness that do not neatly fit disease categories, in which case
syndrome focused guidance or tools will often be relevant. If
the patient described in the table was having falls, for example,
then a more holistic approach that cuts across disease specific
guidance would be appropriate to consider the potential
contribution of both her conditions (atrial fibrillation,
osteoarthritis) and her treatments (antihypertensives, drugs to
control atrial fibrillation, and antidepressants).15
Provide guidance about treatments most
likely to benefit and least likely to harm
Most clinicians use short or quick reference versions of
guidelines that recommend treatments but usually give little
indication of the magnitude of likely benefit, or over what period
benefit accrues and when to consider stopping treatments.
Although the full guidelines do describe the magnitude of
expected benefit, it is usually not easy to compare the absolute
benefit of different treatments, which is what doctors need to
know when deciding on treatment for people taking multiple
medicines or with limited life expectancy. This applies
particularly to preventive treatments rather than treatments for
symptoms (when an individual’s response can be assessed).
Existing guidelines do not routinely summarise clinical and
economic evidence in a way that makes such differences explicit,
which is not helpful in tailoring treatments to an individual
patient’s circumstances and preferences. Consistently
summarising evidence from a variety of sources and different
formats is not easy, but the GRADE summaries used by the
Cochrane Collaboration are an example of such a format.16 One
problem is that although relative risk reduction may be
reasonably stable across populations, absolute benefit varies
widely depending on an individual’s baseline risk of the
outcome. This makes presenting absolute estimates of benefit
like number needed to treat (NNT) difficult in paper guidelines
because multiple numbers need to be shown, which is likely to
be confusing. Electronic guidelines that present the best
information available for individual patients would help reduce
the potential for information overload and confusion.
The table⇓ shows the NNT for our hypothetical patient for the
two preventive drug regimens recommended. Both regimens
are highly effective, but the benefits of oral anticoagulation on
prevention of stroke and total mortality are greater and accrue
more rapidly than treatment of hypertension with up to three
drugs. In many circumstances, clinicians would recommend
both, but actual treatment will vary depending on the patient’s
preferences; these are particularly important for treatments such
as warfarin that require intensive monitoring and modification
of lifestyle.5
Decision making therefore has to appropriately balance clinical
evidence of benefit and harm, and individual preferences.
Critically, both of these may change over time, with the
development of ischaemic heart disease making control of
hypertension relatively more important, or the development of
a life limiting cancer making it less important. Providing
meaningful comparative data on likely benefit and harm in an
individual is not straightforward, but this is again an argument
for systematically embedding what data exist in individualised
guidelines to support clinicians and patients in decision making
rather than providing virtually no data on comparative
effectiveness as currently happens.
Make better use of existing evidence
In practice, there will often not be good evidence of benefit or
harm for individual patients, either because trials systematically
exclude older people and those with multimorbidity17 18 or
because findings are not reported or made available for
meta-analysis stratified by comorbidity. The underlying evidence
could and should be improved by including more older people
in trials17 and by explicitly examining effectiveness in patients
with common comorbidities (as trials of interventions in people
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with diabetes or coronary heart disease and depression
demonstrate19).
However, there are several ways in which existing evidence
could better inform guideline recommendations. Economic
modelling of benefit and harm can be modified to incorporate
information about key patient characteristics and pathways of
care for people with single conditions and multimorbidity. This
may mean, for example, consideration of worse physical
outcomes in people with comorbid depression, or accounting
for reduced life expectancy in people withmultimorbidity where,
for example, a patient with type 2 diabetes and severe heart
failure has minimal chance of receiving any benefit from very
tight glycaemic control but has an immediate risk of harm from
hypoglycaemia. The idea of estimating the time at which slowly
accruing benefits outweigh immediate or constant rate harms
has been applied to cancer screening, but to our knowledge has
not been used in guideline development.9 20
Some of the data required to populate these models will not be
available in the published literature. In this situation, structured
expert elicitation methods can be used that systematically
capture expert knowledge and judgment about uncertain
quantities.21 These methods facilitate the population of an
economic model when data are sparse, but it is vital that the
modelling process includes an explicit measurement of the key
uncertainties in the data and, ideally, uses formal methods to
quantify the value of further research and inform its direction.22
The feasibility and usefulness of these kinds of modelling
approaches requires careful examination, but current approaches
that largely ignore the sickest patients are clearly not optimal.
Conclusion
Clinical decision making requires judgment because evidence
is imperfect, and treatment has to consider patient circumstances,
preferences, and the available healthcare budget. From this
perspective, guidelines will always have limitations, but existing
guidelines can and should be improved as we suggest.
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Table
Table 1| Recommended medium to long term drug treatment for a 76 year old woman with hypertension, atrial fibrillation, osteoarthritis,
and moderately severe depression
Number needed to treatExample cross referencing/important drug interactionsRecommended treatmentCondition
Compared with placebo, 50
people need to be treated
with up to three
antihypertensive drugs for
4.5 years to prevent one
stroke (fatal or non-fatal),
Medicine choice has to be aligned to treatment for atrial
fibrillation
Target blood pressure (BP) <140/90 mm Hg:Hypertension11
Calcium channel blocker
+ ACE inhibitor (if BP uncontrolled)
Increased risk of digoxin toxicity if diuretic induced
hypokalaemia
+ Thiazide-like diuretic (if BP uncontrolled)
+ Spironolactone or other drugs (if BP uncontrolled) and 84 people need to be
treated for 4.5 years to
prevent one death from any
cause23
No evidence for a tighter BP
target24
Spironolactone increases digoxin plasma concentration
Consider risk of falls from treatment15
Compared with placebo, 25
people need to be treated
with an oral anticoagulant
for one year to prevent one
stroke (ischaemic stroke is
reduced, haemorrhagic
Medicine choice has to be aligned to hypertension
treatment
Rate control:Atrial fibrillation
with high untreated
ventricular rate12
β blocker or rate limiting calcium channel blocker
Increased bleeding risk of warfarin or aspirin in combination
with NSAID or SSRI
+ Digoxin if rate remains uncontrolled
Prevention of stroke:
Oral anticoagulation increased), and 59 people
need to be treated for one
year to prevent one death
from any cause25*
Aspirin if patient declines oral anticoagulation Consider risk of falls from condition/rate control treatment15
Effectiveness can be judged
by an individual’s response
to treatment
Increased bleeding risk of oral NSAID in combination with
warfarin, aspirin or SSRI
First line analgesia in conjunction with
non-pharmacological treatments:
Osteoarthritis in
knees and hands
with moderate pain
and functional
limitation13
Oral NSAID may worsen blood pressure controlParacetamol
Topical NSAID
Oral NSAID carries renal risk in combination with ACE
inhibitor and diuretic
Second line analgesia if first line ineffective:
Oral NSAID + PPI
Drug interactions with warfarin (eg, tramadol, PPI)
Oral opiate
Increased risk of constipation from combination of opiates
and calcium channel blockers
Consider risk of falls from condition or opiates15
Effectiveness can be judged
by an individual’s response
to treatment
Bleeding risk of SSRIs in combination with warfarin (avoid)
or aspirin (caution); consider adding gastroprotection with
a proton pump inhibitor
If unresponsive to psychosocial interventions and
supportive care treat with or SSRI or alternative
antidepressant if patient has particular
comorbidities or is prescribed particular other
medicines
Persistent
moderate
depression10 14
Hyponatraemia risk of SSRI in combination with diuretics
ACE=angiotensin converting enzyme; NSAID= non-steroidal anti-inflammatory drug; SSRI= selective serotonin reuptake inhibitor; PPI=proton pump inhibitor.
*Assumes annual stroke risk of 4% based on CHADS2 score of 2.
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Figure
Comorbidity of 10 common conditions among UK primary care patients2
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